作者
Kaitlyn M. Logan,Will Kaplan,Vladimir Simov,Hua Zhou,Derun Li,Luis Ángel Pérula de Torres,Gregori J. Morriello,John J. Acton,Barbara Pio,Yiheng Chen,Mitchell H. Keylor,Rebecca Johnson,Solomon D. Kattar,Ryan Chau,Xin Yan,Michael J. Ardolino,Cayetana Zárate,Karin M. Otte,Rachel L. Palte,Tina Xiong,Spencer E. McMinn,Shishi Lin,Santhosh Neelamkavil,Ping Liu,Jing Su,Laxminarayan G. Hegde,Janice D. Woodhouse,Lily Y. Moy,Paul J. Ciaccio,Jennifer Piesvaux,M. Zebisch,C. H. Henry,John Barker,Harold B. Wood,Matthew Kennedy,Erin F. DiMauro,Matthew Fell,Peter H. Fuller
摘要
Inhibition of leucine-rich repeat kinase 2 is a genetically supported mechanism for the treatment of Parkinson's disease. We previously disclosed the discovery of an indazole series lead that demonstrated both safety and translational risks. The safety risks were hypothesized to be of unknown origin, so structural diversity in subsequent chemical matter was prioritized. The translational risks were identified due to a low brain Kp
不配.
薰硝壤
Singularity
Leonardi
paparazzi221
可靠的书桃
一一
完美的天空
pcr163
HEIKU
寻道图强
咖啡豆
陈军
yufanhui
pluto
8R60d8
tuanheqi
坚强亦丝
sissiarno
Yziii
皖公网安备34019202002308
